Research Progress of PI3K Signaling Pathway Inhibitors in the Treatment of Pulmonary Fibrosis

Yaru SUN; Guangli SHENG; Xuan ZHANG

doi:10.12259/j.issn.2095-610X.S20250620

Volume 46 Issue 6

Jun. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(6): 156-162

Yaru SUN, Guangli SHENG, Xuan ZHANG. Research Progress of PI3K Signaling Pathway Inhibitors in the Treatment of Pulmonary Fibrosis[J]. Journal of Kunming Medical University, 2025, 46(6): 156-162. doi: 10.12259/j.issn.2095-610X.S20250620

Citation:

Yaru SUN, Guangli SHENG, Xuan ZHANG. Research Progress of PI3K Signaling Pathway Inhibitors in the Treatment of Pulmonary Fibrosis[J]. Journal of Kunming Medical University, 2025, 46(6): 156-162. doi: 10.12259/j.issn.2095-610X.S20250620

Citation:

PDF( 903 KB)

Research Progress of PI3K Signaling Pathway Inhibitors in the Treatment of Pulmonary Fibrosis

doi: 10.12259/j.issn.2095-610X.S20250620

School of Pharmaceutical Sciences & Yunnan Key Laboratory of Pharmacology for Natural Products/Yunnan College of Modern Biomedical Industry，Kunming Medical University，Kunming Yunnan 650500，China

Received Date: 2024-12-12
Publish Date: 2025-06-25

Abstract

Abstract

Pulmonary fibrosis （PF） is a chronic progressive lung disease caused by a variety of etiologies and is also a common outcome of various chronic inflammatory lung diseases. The incidence of pulmonary fibrosis is increasing year by year, with a high mortality rate that seriously threatens the life and health of patients. Although two drugs, pirfenidone and nintedanib, are already on the market for the treatment of pulmonary fibrosis, they can only slow down the progression of the disease but cannot reverse or stop the process of pulmonary fibrosis, and long-term use can produce a variety of adverse reactions. Therefore, it is highly necessary to develop new drugs for pulmonary fibrosis that are more targeted, effective, and well-tolerated by patients. The phosphatidylinositol-3-kinase （PI3K） signaling pathway plays an important role in the pathogenesis of pulmonary fibrosis. Targeted inhibition of the PI3K signaling pathway may be an important direction for the development of new drugs for pulmonary fibrosis. At present, some PI3K signaling pathway inhibitors have shown good effects in preventing and treating pulmonary fibrosis, but most of them are still in the research stage. This article reviews the role of the PI3K signaling pathway in PF, further summarizes promising PI3K pathway inhibitors with PF therapeutic effects, including inhibitors in clinical trials and preclinical studies, and discusses their mechanisms of action and development prospects.
- Pulmonary fibrosis,
- PI3K signaling pathway,
- Inhibitors,
- New drug development

FullText(HTML)

References(41)

References

[1]	Koudstaal T,Funke-Chambour M,Kreuter M,et al. Pulmonary fibrosis: From pathogenesis to clinical decision-making[J]. Trends Mol Med,2023,29(12):1076-1087. doi: 10.1016/j.molmed.2023.08.010
[2]	Maher T M,Bendstrup E,Dron L,et al. Global incidence and prevalence of idiopathic pulmonary fibrosis[J]. Respir Res,2021,22(1):197. doi: 10.1186/s12931-021-01791-z
[3]	Lancaster L H,de Andrade J A,Zibrak J D,et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis[J]. Eur Respir Rev,2017,26(146):170057. doi: 10.1183/16000617.0057-2017
[4]	Wind S,Schmid U,Freiwald M,et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib[J]. Clin Pharmacokinet,2019,58(9):1131-1147. doi: 10.1007/s40262-019-00766-0
[5]	Capuzzimati M,Hough O,Liu M. Cell death and ischemia-reperfusion injury in lung transplantation[J]. J Heart Lung Transplant,2022,41(8):1003-1013. doi: 10.1016/j.healun.2022.05.013
[6]	Wang J,Hu K,Cai X,et al. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis[J]. Acta Pharm Sin B,2022,12(1):18-32. doi: 10.1016/j.apsb.2021.07.023
[7]	Margaria J P,Moretta L,Alves-Filho J C,et al. PI3K signaling in mechanisms and treatments of pulmonary fibrosis following sepsis and acute lung injury[J]. Biomedicines,2022,10(4):756. doi: 10.3390/biomedicines10040756
[8]	Li X,Ma X,Miao Y,et al. Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway[J]. J Cell Mol Med,2023,27(3):422-434. doi: 10.1111/jcmm.17665
[9]	Lukey P T,Harrison S A,Yang S,et al. A randomised,placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis[J]. Eur Respir J,2019,53(3):1801992. doi: 10.1183/13993003.01992-2018
[10]	Hettiarachchi S U,Li Y H,Roy J,et al. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models[J]. Sci Transl Med,2020,12(567):eaay3724. doi: 10.1126/scitranslmed.aay3724
[11]	朱武嫦,莫孝成,苏宏梅,等. 天然产物通过抑制PI3K信号通路抗肝纤维化的研究进展[J]. 中国药理学通报,2024,40(4):619-624. doi: 10.12360/CPB202208011
[12]	Zhu K,Wu Y,He P,et al. PI3K/AKT/mTOR-targeted therapy for breast cancer[J]. Cells,2022,11(16):2508. doi: 10.3390/cells11162508
[13]	Xu J,Li Y,Kang M,et al. Multiple forms of cell death: A focus on the PI3K/AKT pathway[J]. J Cell Physiol,2023,238(9):2026-2038. doi: 10.1002/jcp.31087
[14]	Tian L Y,Smit D J,Jücker M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism[J]. Int J Mol Sci,2023,24(3):2652. doi: 10.3390/ijms24032652
[15]	Mei Q,Liu Z,Zuo H,et al. Idiopathic pulmonary fibrosis: An update on pathogenesis[J]. Front Pharmacol,2021,12:797292.
[16]	罗成,叶远航,柯佳. 中药基于PI3K/AKT信号通路治疗肺纤维化的研究进展[J]. 沈阳药科大学学报,2025,42(4):311-321.
[17]	Zhang X L,Li B,Zhang X,et al. 18β-Glycyrrhetinic acid monoglucuronide (GAMG) alleviates single-walled carbon nanotubes (SWCNT)-induced lung inflammation and fibrosis in mice through PI3K/AKT/NF-κB signaling pathway[J]. Ecotoxicol Environ Saf,2022,242:113858. doi: 10.1016/j.ecoenv.2022.113858
[18]	Pan L,Cheng Y,Yang W,et al. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis,inflammation,apoptosis,and oxidative stress by modulating PI3K/Akt/mTOR pathway in mice[J]. Inflammation,2023,46(4):1531-1542. doi: 10.1007/s10753-023-01825-2
[19]	Rahmani F,Asgharzadeh F,Avan A,et al. Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways[J]. Life Sci,2020,249:117470. doi: 10.1016/j.lfs.2020.117470
[20]	Huckestein B R,Zeng K,Westcott R,et al. Mammalian target of rapamycin complex 1 activation in macrophages contributes to persistent lung inflammation following respiratory tract viral infection[J]. Am J Pathol,2024,194(3):384-401. doi: 10.1016/j.ajpath.2023.11.017
[21]	Cadena-Suárez A R,Hernández-Hernández H A,Alvarado-Vásquez N,et al. Role of microRNAs in signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis: A focus on epithelial-mesenchymal transition[J]. Int J Mol Sci,2022,23(12):6613. doi: 10.3390/ijms23126613
[22]	朱雨晴,韩彦琪,韩梁,等. 中药通过抑制上皮间充质转化缓解肺纤维化的研究进展[J]. 中草药,2025,56(7):2559-2570.
[23]	Sun H N,Ren C X,Lee D H,et al. PRDX1 negatively regulates bleomycin-induced pulmonary fibrosis via inhibiting the epithelial-mesenchymal transition and lung fibroblast proliferation in vitro and in vivo[J]. Cell Mol Biol Lett,2023,28(1):48. doi: 10.1186/s11658-023-00460-x
[24]	Weng C M,Li Q,Chen K J,et al. Bleomycin induces epithelial-to-mesenchymal transition via bFGF/PI3K/ESRP1 signaling in pulmonary fibrosis[J]. Biosci Rep,2020,40(1):BSR20190756. doi: 10.1042/BSR20190756
[25]	Zhao H,Wang Y,Qiu T,et al. Autophagy,an important therapeutic target for pulmonary fibrosis diseases[J]. Clin Chim Acta,2020,502:139-147. doi: 10.1016/j.cca.2019.12.016
[26]	Peng J,Xiao X,Li S,et al. Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway[J]. Exp Gerontol,2023,172:112085. doi: 10.1016/j.exger.2023.112085
[27]	Gong H,Lyu X,Liu Y,et al. Eupatilin inhibits pulmonary fibrosis by activating Sestrin2/PI3K/Akt/mTOR dependent autophagy pathway[J]. Life Sci,2023,334:122218. doi: 10.1016/j.lfs.2023.122218
[28]	Alsayed H A,Mohammad H M F,Khalil C M,et al. Autophagy modulation by irbesartan mitigates the pulmonary fibrotic alterations in bleomycin challenged rats: Comparative study with rapamycin[J]. Life Sci,2022,303:120662. doi: 10.1016/j.lfs.2022.120662
[29]	Li P,Hao X,Liu J,et al. miR-29a-3p regulates autophagy by targeting Akt3-mediated mTOR in SiO(2)-induced lung fibrosis[J]. Int J Mol Sci,2023,24(14):11440. doi: 10.3390/ijms241411440
[30]	Campa C C,Silva R L,Margaria J P,et al. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis[J]. Nat Commun,2018,9(1):5232. doi: 10.1038/s41467-018-07698-6
[31]	Lin S,Jin J,Liu Y,et al. Discovery of 4-methylquinazoline based PI3K inhibitors for the potential treatment of idiopathic pulmonary fibrosis[J]. J Med Chem,2019,62(19):8873-8879. doi: 10.1021/acs.jmedchem.9b00969
[32]	Zhang W,Zhang Y,Tu T,et al. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis[J]. Cell Death Dis,2020,11(9):765. doi: 10.1038/s41419-020-02916-w
[33]	Xu Z,Lv Y,Kong D,et al. Sapanisertib attenuates pulmonary fibrosis by modulating Wnt5a/mTOR signalling[J]. Basic & Clinical Pharmacology & Toxicology,2023,133(3):226-236.
[34]	Pandolfi L,Marengo A,Japiassu K B,et al. Liposomes loaded with everolimus and coated with hyaluronic acid: A promising approach for lung fibrosis[J]. Int J Mol Sci,2021,22(14):7743. doi: 10.3390/ijms22147743
[35]	González-Sánchez E,Muñoz-Callejas A,Gómez-Román J,et al. Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice[J]. Br J Pharmacol,2022,179(18):4534-4548. doi: 10.1111/bph.15898
[36]	Shaikh T B,Chandra Y,Andugulapati S B,et al. Vistusertib improves pulmonary inflammation and fibrosis by modulating inflammatory/oxidative stress mediators via suppressing the mTOR signalling[J]. Inflamm Res,2024,73(7):1223-1237. doi: 10.1007/s00011-024-01894-5
[37]	Gomez-Manjarres D C,Axell-House D B,Patel D C,et al. Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial[J]. JCI Insight,2023,8(8):e166901. doi: 10.1172/jci.insight.166901
[38]	He Y,Sun M M,Zhang G G,et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Signal Transduct Target Ther,2021,6(1):425. doi: 10.1038/s41392-021-00828-5
[39]	Xie J,Xu K,Cai Z,et al. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: A multicenter propensity score matched retrospective study[J]. Transl Lung Cancer Res,2024,13(3):526-539. doi: 10.21037/tlcr-24-24
[40]	Zhang L,Li Y,Hu C,et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells[J]. Mol Cancer,2022,21(1):103. doi: 10.1186/s12943-022-01524-w
[41]	Huang T,Gao J,Cai L,et al. Treating pulmonary fibrosis with non-viral gene therapy: From bench to bedside[J]. Pharmaceutics,2022,14(4):813. doi: 10.3390/pharmaceutics14040813

Relative Articles(20)

Relative Articles

[1]	Haixing ZHANG, Jingyun ZHANG, Dandan XU, Lu CAO, Jingjing LI. The Mechanism of miR-23 Regulating PI3K/AKT/mTOR Pathway to Improve Myocardial Angiogenesis in Hypertensive Heart Failure Rats. Journal of Kunming Medical University, 2025, 46(11): 35-42. doi: 10.12259/j.issn.2095-610X.S20251105
[2]	Egao YIN, Wen LEI, Mei YANG, Yongjun LIU, Zhaoxing DONG. Effect of mTOR Signaling Pathway Inhibition on Bleomycin-induced Pulmonary Fibrosis. Journal of Kunming Medical University, 2025, 46(6): 64-70. doi: 10.12259/j.issn.2095-610X.S20250608
[3]	Zhixiao LI, Xia ZHENG, Chunling LI, Qingsheng LIU, Heng ZHANG. The Molecular Mechanism of miR-205-5p Targeting ERBB3 to Regulate PI3K/AKT/mTOR Pathway and Inhibit Angiogenesis in Hemorrhoids. Journal of Kunming Medical University, 2024, 45(6): 22-35. doi: 10.12259/j.issn.2095-610X.S20240604
[4]	Weimin LIU, Yiqun MA, Zhuo TIAN, Yang TANG. Regulatory Role of PI3K/Akt Signaling Pathway in Hypertrophic Scar. Journal of Kunming Medical University, 2023, 44(3): 22-27. doi: 10.12259/j.issn.2095-610X.S20230313
[5]	Cong LIU, Guishuai WU, Rui PU, Shude LI, Jianping TAO, Renfa ZHANG. EGCG Improves Myocardial Fibrosis Induced by High Fat and High Sugar Diet in Obese Rats by Inhibiting TGF-β1/Smads Signaling Pathway. Journal of Kunming Medical University, 2022, 43(5): 18-26. doi: 10.12259/j.issn.2095-610X.S20220506
[6]	Yegang HU, Wei ZHANG. Role of Hereditary T Lymphocyte Immune Deficiency in Pulmonary Fibrosis Induced by Paraquat. Journal of Kunming Medical University, 2022, 43(4): 6-11. doi: 10.12259/j.issn.2095-610X.S20220402
[7]	Na PI, Qin HE, Yan ZHONG, Xuan JIN, Zhen-dong ZHU, Xuan ZHANG. Effect of Gentiana Rigescens Franch on Expression of NF - κ B and CTGF in Lung Tissue of Mice with Pulmonary Fibrosis. Journal of Kunming Medical University, 2021, 42(4): 8-12. doi: 10.12259/j.issn.2095-610X.S20210402
[8]	Yong-jun LIU, Yin WANG, Mei YANG, E-gao YIN, Ting LI, Zhao-xing DONG. The Effect of Hydrogen-Regulated Autophagy on Pulmonary Fibrosis in Paraquat Poisoned Rats. Journal of Kunming Medical University, 2021, 42(9): 1-6. doi: 10.12259/j.issn.2095-610X.S20210918
[9]	Li Ting , Deng Shu Hao , Liu Yong Jun , Dong Zhao Xing . . Journal of Kunming Medical University, 2019, 40(08): 1-5.
[10]	Tai Wen Lin , Ding Jia Wei , Zheng Bo Yang , Wu Han Xin , Gao Ling , Zhang Wei , Dong Zhao Xing , Xu Yi Heng . . Journal of Kunming Medical University, 2017, 38(03): 21-26.
[11]	Wang Ya Nan , Li Zhi Gang , Zhang Chao , Li Shu De , Li Tao , Peng Jian Zhi . Homocysteine Suppress PI3K/Akt Signaling Pathway via Promoting the Expression of TRB3 in Adipose Tissue. Journal of Kunming Medical University, 2017, 38(06): 15-18.
[12]	Wang Ying Xia . Anti-fibrotic Effect of Kudancao Tablets on Bleomycin-induced Pulmonary Fibrosis in Rats. Journal of Kunming Medical University,
[13]	Lei Wen . IL-27 Alleviates the Bleomycin-induced Pulmonary Fibrosis through Regulating TGF-β/Smad Signaling Pathway. Journal of Kunming Medical University,
[14]	Song Xin Huan . . Journal of Kunming Medical University,
[15]	He Xiao Yu . . Journal of Kunming Medical University,
[16]	Dong Zhao Xing . . Journal of Kunming Medical University,
[17]	Gu Wan Gang . . Journal of Kunming Medical University,
[18]	Gu Wan Gang . . Journal of Kunming Medical University,
[19]	Gu Wan Gang . . Journal of Kunming Medical University,
[20]	Zhang Ji Zhou . Effect of Exogenous Carbon Monoxide on Gaseous Signaling Molecules in Hippocampus of Rats with Cerebral Ischemic-Reperfusion Injury. Journal of Kunming Medical University,